Agenus Inc.
Lexington, MA · CIK 0001098972 · Medtech
PET imaging agent using radiolabeled single-domain antibodies to visualize PD-L1 expression in tumors
agenus.bio →- Grants
- $1.2M
- 4 awards
- Sector median: 1
- Raised
- $221M
- 11 Form D · Feb 2019
- 92 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 21 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200920112013201520172019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $10,000,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $35,000,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $21,140,000 | |
| Private capital raised | Form D · SEC | $2,142,000 | |
| Private capital raised | Form D · SEC | $7,400,090 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant· 1 of 4 same day | Department of Health and Human Services · Phase I · Development of immuno-PET agents for the selective imaging of CD8 T cells | $300,000 | |
| Federal grant· 2 of 4 same day | Department of Health and Human Services · Phase I · Validation and humanization of a PET imaging agent that targets PD-L1. | $300,000 | |
| Federal grant· 3 of 4 same day | Department of Health and Human Services · Phase I · Validation and humanization of a PET imaging agent that targets PD-L1. | $300,000 | |
| Federal grant· 4 of 4 same day | Department of Health and Human Services · Phase I · Development of immuno-PET agents for the selective imaging of CD8 T cells | $300,000 | |
| Private capital raised | Form D · SEC | $60,000,000 | |
| Private capital raised | Form D · SEC | $40,000,653 | |
| Private capital raised | Form D · SEC | $30,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1690 | NEUROMUSCULAR DYNAMICS LLC | — | — |
| 1691 | Radiologics, Inc. | — | — |
| 1692 | NATURAL NIPPLE CORP., THE | — | — |
| 1693 | Agenus Inc. | — | $221M |
| 1694 | INTEGUMED, LLC | — | — |
| 1695 | ZBEATS, INC. | — | — |
| 1696 | MOLECULAR SURFACE TECHNOLOGIES LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Garo ArmenDirector · Executive Officer
- GARO ARMENDirector · Executive Officer
- Charles BallantyneExecutive Officer
- Ozer BaysalExecutive Officer
- Jennifer BuellExecutive Officer
- Christian CortisExecutive Officer
- Brian CorveseDirector
- BRIAN CORVESEDirector
- Tom DechaeneDirector
- TOM DECHAENEDirector
- Alex DuncanExecutive Officer
- John HatsopoulosDirector
- Allison Jeynes-EllisDirector
- Wadih JordanDirector
- WADIH JORDANDirector
- Evan KearnsExecutive Officer
- Christine KlaskinExecutive Officer
- CHRISTINE KLASKINExecutive Officer
- Hyam Levitsky, M.DDirector
- Hyam Levitsky, M. D.Director
- Shahzad MalikDirector
- Timothy RothwellDirector
- Shalini SharpDirector · Executive Officer
- SHALINI SHARPDirector
- Robert SteinExecutive Officer
- Karen ValentineExecutive Officer
- KAREN VALENTINEExecutive Officer
- Kerry WentworthExecutive Officer
- KERRY WENTWORTHExecutive Officer
- Ulf WiinbergDirector
- Timothy WrightDirector
- TIMOTHY WRIGHTDirector
Patents
- Methods Of Treating Pancreatic Cancer Using An ANTI-CTLA4 Antibodyapplication
- Anti-tigit Antibodies And Methods Of Use Thereofgranted
- Methods Of Treating Cancer Using An ANTI-CTLA4 Antibody And An ENPP1 Inhibitorapplication
- Fibroblast Activation Protein (fap) Car-invariant Natural Killer T Cells And Uses Thereofapplication
- Methods Of Treating Melanoma Using An ANTI-CTLA4 Antibodyapplication
- ANTI-CD137 Antibodies And Methods Of Use Thereofgranted
- Polynucleotide Encoding Anti-tigit And ANTI-CD96 Antibodiesgranted
- Methods Of Treating Colorectal Cancer Using An ANTI-CTLA4 Antibodyapplication
- ANTI-ILT4 Antibodies And Antigen-binding Fragmentsgranted
- ANTI-LAG-3 Antibodies And Methods Of Use Thereofapplication
- ANTI-ILT2 Antibodies And Uses Thereofapplication
- ANTI-LAG-3 Antibodies And Methods Of Use Thereofgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.